Trump Moves to Replace FDA Chief Makary After Vape Approval Dispute

Context The FDA has faced internal turbulence this year, with debates over vaccine authorizations, gene therapy rulings, abortion pill oversight, and vape regulation. Makary’s reluctance to swiftly approve menthol, mango, and blueberry vape flavors from Los Angeles‑based Glas drew Trump’s ire, leading to a public scolding over the weekend. After pressure, the agency authorized those products on Tuesday.

Key Facts Trump’s administration has approved a plan to remove Makary, though officials note the decision remains provisional and could be altered. The president accused Makary of moving too slowly on flavored vapes and nicotine products, framing the delay as a breach of his campaign pledge to “save vaping.” If Makary departs, the FDA would join the CDC, which currently lacks a director, and the nation would still have no surgeon general, compounding vacancies across top health agencies.

What It Means The potential leadership shake‑up could further destabilize federal health policy amid ongoing debates about youth vaping, drug approvals, and public health messaging. Stakeholders will watch for an acting FDA appointee, any legal challenges to the removal, and how the administration balances industry pressure with regulatory safeguards.

What to watch next: Whether the White House finalizes the dismissal, who steps in as acting FDA commissioner, and how the agency proceeds with pending vape and nicotine product reviews.